Shannon T Kelley sold $480k of MDGL
General Counsel at MADRIGAL PHARMACEUTICALS, INC.. 1,304 shares at an average of $367.81, traded Aug 18, 2025, filed Aug 18, 2025.
Score components
- +15RoleOfficer
- +18Trade size$480k at market
- +5Share of holdings soldSold 12% of holdings
- +15Cluster5 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0002034056-25-000009, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 18, 2025 | SOpen-market sale Common Stock10b5-1 | -458 | $358.66 | $164k | 10,019 | Aug 18, 2025 |
| Aug 18, 2025 | SOpen-market sale Common Stock10b5-1 | -126 | $369.64 | $47k | 9,893 | Aug 18, 2025 |
| Aug 18, 2025 | SOpen-market sale Common Stock10b5-1 | -84 | $370.06 | $31k | 9,809 | Aug 18, 2025 |
| Aug 18, 2025 | SOpen-market sale Common Stock10b5-1 | -84 | $371.35 | $31k | 9,725 | Aug 18, 2025 |
| Aug 18, 2025 | SOpen-market sale Common Stock10b5-1 | -252 | $372.44 | $94k | 9,473 | Aug 18, 2025 |
| Aug 18, 2025 | SOpen-market sale Common Stock10b5-1 | -68 | $374.13 | $25k | 9,405 | Aug 18, 2025 |
| Aug 18, 2025 | SOpen-market sale Common Stock10b5-1 | -190 | $375.75 | $71k | 9,215 | Aug 18, 2025 |
| Aug 18, 2025 | SOpen-market sale Common Stock10b5-1 | -42 | $376.62 | $16k | 9,173 | Aug 18, 2025 |
Related signals
Other insiders at MADRIGAL PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | MADRIGAL PHARMACEUTICALS, INC. | William John Sibold President and CEO | $6.2M 11,583 shares | -6% | |
| 25Weak | MADRIGAL PHARMACEUTICALS, INC. | Paul A Friedman director | $14M 24,800 shares | -12% | |
| 20Weak | MADRIGAL PHARMACEUTICALS, INC. | Rebecca Taub director | $10M 18,650 shares | -4% | |
| 50Moderate | MADRIGAL PHARMACEUTICALS, INC. | William John Sibold President and CEO | $1.4M 2,400 shares | -2% | |
| 37Weak | MADRIGAL PHARMACEUTICALS, INC. | Mardi Dier EVP and CFO | $2.4M 4,173 shares | -29% | |
| 40Moderate | MADRIGAL PHARMACEUTICALS, INC. | Carole Huntsman Chief Commercial Officer | $1.1M 1,958 shares | -16% | |
| 30Weak | MADRIGAL PHARMACEUTICALS, INC. | Richard S Levy director | $4.4M 8,500 shares | -29% | |
| 53Moderate | MADRIGAL PHARMACEUTICALS, INC. | Kenneth Bate director | $8.0M 16,575 shares | -86% | |
| 50Moderate | MDGLsell MADRIGAL PHARMACEUTICALS, INC. | William John Sibold President and CEO | $3.2M 7,279 shares | -7% | |
| 45Moderate | MADRIGAL PHARMACEUTICALS, INC. | William John Sibold President and CEO | $3.0M 7,616 shares | -6% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.